Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lipocine Inc. Director's Dealing 2018

Dec 6, 2018

35074_dirs_2018-12-06_d9698aad-d013-4bb1-8680-a77af25af0d7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lipocine Inc. (LPCN)
CIK: 0001535955
Period of Report: 2018-12-04

Reporting Person: Patel Mahesh V. (Director, President and CEO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-12-04 Restricted stock unit $0 A 290000 Acquired 2028-12-04 Common Stock (290000) Direct
2018-12-04 Stock Option (Right to Buy) $1.46 A 150000 Acquired 2028-12-04 Common Stock (150000) Direct

Footnotes

F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit

F2: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020.

F3: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 4, 2019, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.